{"id":708,"date":"2024-09-29T14:00:24","date_gmt":"2024-09-29T14:00:24","guid":{"rendered":"http:\/\/cetaitdemain.org\/?p=708"},"modified":"2024-09-29T14:00:24","modified_gmt":"2024-09-29T14:00:24","slug":"the-300-and-150-cells-l-subgroups-showed-lower-percentages-of-transitioning-patients-with-20-and-30-transitioning-to-other-eosinophil-subgroups-at-any-point-in-time","status":"publish","type":"post","link":"https:\/\/cetaitdemain.org\/?p=708","title":{"rendered":"\ufeffThe ?300 and 150 cells\/l subgroups showed lower percentages of transitioning patients, with 20% and 30% transitioning to other eosinophil subgroups at any point in time"},"content":{"rendered":"

\ufeffThe ?300 and 150 cells\/l subgroups showed lower percentages of transitioning patients, with 20% and 30% transitioning to other eosinophil subgroups at any point in time. In the 150 and ?300 cells\/l subgroups, transitioning occurred most often between adjacent eosinophil subgroups. time points. The ?300 and 150 cells\/l subgroups showed lower percentages of transitioning patients, with 20% and 30% transitioning to other eosinophil subgroups at any point in time. In the 150 and ?300 cells\/l subgroups, transitioning occurred most often between adjacent eosinophil subgroups. In patients with eosinophil counts 150 cells\/l, 30% of patients transitioned to the 150C299 cells\/l subgroup, and 20% of patients with eosinophil counts ?300 cells\/l transitioned to the 150C299 cells\/l subgroup. However, Thevetiaflavone transitions to nonadjacent subgroups also occurred from Thevetiaflavone the 150 to the ?300 cells\/l subgroup and from the ?300 to the 150 cells\/l subgroup. Transitions to nonadjacent subgroups were less common, with only 6% and 4% of patients in the 150 Thevetiaflavone<\/a> and ?300 cells\/l subgroups transitioning to the ?300 and 150 cells\/l subgroups, respectively. Patients in the 150C299 cells\/l subgroup had an almost equal likelihood (20%) of transitioning Thevetiaflavone to the 150 and ?300 cells\/l subgroups (Figure 3B). In a sensitivity analysis excluding patients treated with oral corticosteroids for an exacerbation during the study, the proportion of patients remaining in the 150, 150C299, and ?300 cells\/l subgroups for ?60%, ?70%, ?80%, and ?90% of the time was similar to the analysis of the total population. Furthermore, the 150C299 cells\/l subgroup showed a similar degree of instability versus the 150 and ?300 cells\/l subgroups (Table 2). Technical Variability Although blood eosinophils are used in asthma management, the assays to measure eosinophils were not developed for this purpose. Because technical variation may have an impact on reliability of eosinophil counts, we studied differences between laboratories and associated variables. Eosinophil counts from 62 subjects measured at 10 different laboratories were Rabbit Polyclonal to TISB (phospho-Ser92)<\/a> compared. There was good association between eosinophil counts measured at laboratory A versus all other laboratories (Spearmans correlation coefficient: minimum, indicates patients whose diagnosis of eosinophilic asthma (based on a 300 cells\/l cutoff) is dependent upon the laboratory. (values, making observations less certain. The prespecified threshold was fairly large (50 cells\/l), which may have resulted in having missed variables that may also be important. The retrospective nature of these analyses also potentially makes these data more prone to confounding and bias. Furthermore, only a few aspects of technical variability were included, and it is unknown whether other factors, such as ethylenediaminetetraacetic acid tube filling and mixing, transportation, and sample preparation, may have contributed to the differences observed (16, 46). Conclusions This study adds to a body of evidence suggesting that eosinophil counts are variable and may be influenced by multiple factors, including nasal polyps, smoking, seasonality, natural variation over time, and analytical factors. If eosinophil counts are used for diagnosis or management of eosinophilic asthma, a single blood eosinophil measurement may not be sufficient and should be interpreted in the context of each patients medical history. Acknowledgment The authors thank Nicole Tom, Ph.D., of Envision Pharma Inc., for providing third-party writing assistance, which was funded by Genentech, Inc., a member of the Roche Group, and Novartis Pharmaceuticals Corporation. Footnotes Supported by Genentech, Inc. The included studies (LUTE and VERSE) and this analysis were funded by Genentech, Inc., a member of the Roche Group, and Novartis Pharma AG. em Author Contributions \/em : Study concept and design: A.I., T.H., M.Y., J.B., and C.T.J.H.. Data analysis: M.Y. Critical review of data, manuscript drafts, and final approvals on submitted manuscript: B.E.C., N.J., W.J.C., A.I., T.H., M.Y., J.B., J.C., C.T.J.H., and M.B. Data sharing statement: Qualified researchers may request access to individual patient.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffThe ?300 and 150 cells\/l subgroups showed lower percentages of transitioning patients, with 20% and 30% transitioning to other eosinophil subgroups at any point in time. In the 150 and ?300 cells\/l subgroups, transitioning occurred most often between adjacent eosinophil subgroups. time points. The ?300 and 150 cells\/l subgroups showed lower percentages of transitioning patients, …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-708","post","type-post","status-publish","format-standard","hentry","category-peptide-receptor-other","entry entry-center"],"_links":{"self":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=708"}],"version-history":[{"count":1,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/708\/revisions"}],"predecessor-version":[{"id":709,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/708\/revisions\/709"}],"wp:attachment":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}